Hims & Hers Health (HIMS) Faces FTC Lawsuit, Is The Stock Now A Bargain?

September 12, 2026 - 17:11

Hims & Hers Health is dealing with serious legal trouble after the Federal Trade Commission filed a lawsuit on July 29, 2026. The complaint alleges improper handling of health data and questionable billing practices. A shareholder class action has followed, adding another layer of pressure on the company.

The legal issues arrive at a difficult moment. The stock was already losing momentum before the FTC news broke. Shares closed at US$27.51. Over the past month, the share price return is down 8.21%. The one year total shareholder return has fallen 50.43%, a steep drop after an enormous three year run.

Investors now face a familiar question. Is this a buying opportunity or a warning sign? The company built its reputation on convenient access to prescription treatments and telehealth services. That model attracted millions of customers and drove rapid growth. But regulatory scrutiny can change the math quickly. Data privacy and billing complaints strike at the core of consumer trust.

The FTC action could lead to fines, operational changes, or both. The class action adds legal costs and management distraction. For now, the market is treating the situation as a risk rather than a discount. Whether Hims & Hers can stabilize depends on how it responds to the allegations and whether growth can offset the mounting legal overhang.